Media coverage about Agios Pharmaceuticals (NASDAQ:AGIO) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Agios Pharmaceuticals earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.6406414491367 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the headlines that may have effected Accern’s analysis:
- Fighting Cancer One Patient At A Time (finance.yahoo.com)
- Agios Posts New Data on Glioma Candidate from Dose Expansion – Nasdaq (nasdaq.com)
- Biotech Stock Performance Review — Achillion Pharma, Aduro BioTech, Agios … (prnewswire.com)
- Agios Pharmaceuticals Enters Oversold Territory (AGIO) (nasdaq.com)
- Agios Pharmaceuticals, Inc. (AGIO) PT Set at $80.00 by SunTrust Banks, Inc. (americanbankingnews.com)
Shares of Agios Pharmaceuticals (AGIO) traded up $1.59 during trading hours on Tuesday, hitting $60.18. The stock had a trading volume of 278,941 shares, compared to its average volume of 524,264. Agios Pharmaceuticals has a 52 week low of $39.24 and a 52 week high of $72.73.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.78) by $0.19. Agios Pharmaceuticals had a negative return on equity of 64.54% and a negative net margin of 679.14%. The company had revenue of $11.35 million during the quarter, compared to analyst estimates of $10.85 million. During the same period last year, the company posted ($1.63) earnings per share. The firm’s quarterly revenue was up 26.4% compared to the same quarter last year. sell-side analysts predict that Agios Pharmaceuticals will post -6.59 EPS for the current year.
Several research analysts have issued reports on AGIO shares. BidaskClub lowered Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. SunTrust Banks, Inc. reiterated a “buy” rating and set a $80.00 price objective (up from $68.00) on shares of Agios Pharmaceuticals in a research note on Tuesday, August 8th. Needham & Company LLC increased their price objective on Agios Pharmaceuticals from $54.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, August 10th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $83.00 price objective (up from $75.00) on shares of Agios Pharmaceuticals in a research note on Thursday, August 10th. Finally, Leerink Swann upgraded Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $50.00 to $80.00 in a research note on Wednesday, August 2nd. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $75.70.
WARNING: This report was first posted by Week Herald and is owned by of Week Herald. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://weekherald.com/2017/11/21/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-agios-pharmaceuticals-agio-stock-price.html.
In related news, Director Lewis Clayton Jr. Cantley sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $56.85, for a total value of $227,400.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO David P. Schenkein sold 80,000 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $70.14, for a total value of $5,611,200.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 182,908 shares of company stock valued at $12,391,239. 10.55% of the stock is currently owned by corporate insiders.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.